1. Home
  2. INO vs SPRO Comparison

INO vs SPRO Comparison

Compare INO & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inovio Pharmaceuticals Inc.

INO

Inovio Pharmaceuticals Inc.

HOLD

Current Price

$1.58

Market Cap

116.1M

Sector

Health Care

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.33

Market Cap

129.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INO
SPRO
Founded
1979
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.1M
129.6M
IPO Year
1998
2017

Fundamental Metrics

Financial Performance
Metric
INO
SPRO
Price
$1.58
$2.33
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
1.1M
344.4K
Earning Date
03-17-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$182,337.00
$40,549,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$23,060.18
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.30
$0.51
52 Week High
$2.98
$3.22

Technical Indicators

Market Signals
Indicator
INO
SPRO
Relative Strength Index (RSI) 43.10 50.55
Support Level $1.54 $2.28
Resistance Level $1.78 $2.43
Average True Range (ATR) 0.11 0.12
MACD 0.02 0.01
Stochastic Oscillator 32.79 65.38

Price Performance

Historical Comparison
INO
SPRO

About INO Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: